Highest-materiality recent filing
Autolus 2026 AGM passes all resolutions, re-elects directors and approves auditors
Adopted 2025 annual accounts: 165,846,326 for, 2,895,344 against.
Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay
AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.
Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M
Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings
Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
Autolus Therapeutics dismisses EY UK and appoints EY US as independent auditor
Audit committee dismissed EY UK on April 14, 2026; no disagreements or reportable events in prior two fiscal years.
Autolus hosts ALL Business investor event; presentation lacks specific financial data
Virtual investor event held on April 8, 2026, titled 'Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business'.
Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M
Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
Autolus enters 10-year lentiviral vector supply deal with AGC Biologics
Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.
Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M
Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
Autolus appoints former BioNTech CSO Ryan Richardson to Board
Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).
Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission
Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold
Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
Autolus Therapeutics announces results of 2025 Annual General Meeting, all resolutions passed
Resolution 1 (adopt 2024 accounts): 219,809,664 for, 97,503 against, 477,332 abstain.
Autolus sets AGM for June 26; two directors to step down; new equity plan proposed
AGM on June 26, 2025; resolutions include adoption of 2024 accounts, auditor reappointment (EY LLP), and director re-elections.
Autolus directors Anderson and Murphy will not stand for re-election at 2025 AGM
Joseph Anderson and Martin Murphy notified the board on May 23, 2025, of their decision.
Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL
Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.
Autolus schedules R&D investor event with corporate update; no specific data disclosed
Corporate update presented at R&D investor event on April 23, 2025.
Autolus Therapeutics VP Finance resigns; CFO Dolski appointed PAO
Andrew Mercieca resigned as VP Finance & PAO on Feb 24, 2025, effective August 2025; not due to any disagreement.
Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers
Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).
Autolus presents at JPM Health Conference; no material news in 8-K
Autolus presented corporate update at J.P. Morgan Health Conference on Jan 13, 2025.
FDA approves Autolus' AUCATZYL (obe-cel) for adult r/r B-ALL; no REMS required
Approval based on FELIX trial: 63% overall complete remission (CR/CRi) in efficacy-evaluable patients (n=65); median DOR 14.1 months.
Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone
FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.
Autolus presents corporate update at KBC Life Sciences Conference; limited exhibit provided
Corporate presentation made at KBC Life Sciences Conference on September 26, 2024.
Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer
Dr. Will joins as CDO effective September 30, 2024.
Autolus secures up to £18.5M landlord funding for Nucleus facility clean rooms
Landlord provides up to £18.5M for improvements to Stevenage manufacturing facility.
Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track
Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.
Autolus Therapeutics shareholders approve all nine resolutions at 2024 AGM
Adoption of 2023 annual accounts passed with 190.78M votes for, 35.8K against.
Autolus publishes UK Annual Report; provides obe-cel BLA status, PDUFA date Nov 16, 2024
BLA for obe-cel accepted by FDA; PDUFA target action date set for 16 November 2024.
Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months
ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.
Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16
Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.
Autolus Therapeutics delays Q1 2024 filing; cancels May 14 earnings call, reschedules to May 17
Plans to file Form 12b-25 for automatic 5-day extension of Q1 2024 10-Q due May 15.
John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.
Autolus restates 2021-2022 financials on R&D tax credit classification error
Error: UK SME R&D tax credits previously classified as income tax benefit should reduce R&D expense instead.
Autolus files 8-K/A to furnish Q4 2023 earnings call transcript; no new financial details
Amendment filed solely to furnish transcript of March 14, 2024 FY2023 earnings call.
Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns
Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.
Autolus posts updated corporate presentation; no material new details available
Company posted updated corporate presentation to its website on February 13, 2024.
Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech
BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.
Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development
Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.
Autolus Therapeutics announces FDA acceptance of BLA for obe-cel; PDUFA date Nov 16, 2024
FDA accepted BLA for obe-cel in relapsed/refractory Adult B-ALL; PDUFA target action date November 16, 2024.
Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted
Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.
Autolus appoints Elisabeth Leiderman to board; Kapil Dhingra resigns
Kapil Dhingra resigned from Board effective Dec 31, 2023; not due to any disagreement with company.
Pooled FELIX Phase Ib/II (n=127): CR/CRi rate 78%; grade ≥3 CRS 2%, ICANS 7%; median follow-up 16.6 months.
Autolus submits BLA to FDA for cell therapy obe-cel in r/r adult B-ALL
BLA for obecabtagene autoleucel (obe-cel) submitted to FDA for relapsed/refractory adult B-cell ALL.
Autolus voluntarily elects U.S. domestic issuer reporting, no change to Q3 2023 financials
Autolus will file periodic reports on Forms 10-K, 10-Q, and 8-K instead of foreign private issuer forms.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.
On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.
On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.
appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.
appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.
appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.
On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.
On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.
Max materiality 0.90 · Median 0.57 · Most common event other_material